Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity,
especially in genetic alteration and microenvironment. Conventional therapeutic strategies …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

The molecular mechanisms underlying cancer immune escape are a core topic in cancer
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …

The MET gene, known as MET proto-oncogene receptor tyrosine kinase, was first identified
to induce tumor cell migration, invasion, and proliferation/survival through canonical RAS …

Background Chemoradiotherapy‐induced PD‐L1 upregulation leads to therapeutic
resistance and treatment failure. The PD‐1/PD‐L1 blocking antibodies sensitize cancers to …

The identification of gasdermin as the executor of pyroptosis has opened new avenues for
the study of this process. Although pyroptosis research has mainly focused on immune cells …

Background LTX-315 is an oncolytic peptide deriving from bovine lactoferrin, with the ability
to induce cancer immunogenic cell death. However, the mechanism used by LTX-315 to …

Pancreatic cancer (PC) is a deadly cancer with a high mortality rate. The unique
characteristics of PC, including desmoplasia and immunosuppression, have made it difficult …

Immunoglobulin G (IgG) is the predominant component in humoral immunity and the major
effector of neutralizing heterogeneous antigens. Glycosylation, as excessive …

Combinational therapy has improved the cancer therapeutic landscape but is associated
with a concomitant increase in adverse side reactions. Emerging evidence proposes that …